(Q44144794)

30 November 2017

title

Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward (English)

1 reference

30 November 2017

0 references

1 reference

1 reference

Julia K Nunes

1

1 reference

30 November 2017

Colleen Woods

2

1 reference

30 November 2017

Terrell Carter

3

1 reference

30 November 2017

Theresa Raphael

4

1 reference

30 November 2017

Merribeth J Morin

5

1 reference

30 November 2017

Diadier Diallo

6

1 reference

30 November 2017

Didier Leboulleux

7

1 reference

30 November 2017

Sanjay Jain

8

1 reference

30 November 2017

Christian Loucq

9

1 reference

30 November 2017

David C Kaslow

10

1 reference

30 November 2017

Ashley J Birkett

11

1 reference

30 November 2017

language of work or name

English

0 references

publication date

29 July 2014

1 reference

30 November 2017

1 reference

30 November 2017

volume

32

1 reference

30 November 2017

issue

43

1 reference

30 November 2017

page(s)

5531-5539

1 reference

Malaria. Did they really say ... eradication?

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A Research Agenda to Underpin Malaria Eradication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A research agenda for malaria eradication: cross-cutting issues for eradication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A research agenda for malaria eradication: health systems and operational research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A research agenda for malaria eradication: modeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A research agenda for malaria eradication: drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A research agenda for malaria eradication: monitoring, evaluation, and surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A research agenda for malaria eradication: diagnoses and diagnostics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A research agenda for malaria eradication: basic science and enabling technologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A research agenda for malaria eradication: vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A research agenda for malaria eradication: vector control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Transmission-blocking interventions eliminate malaria from laboratory populations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Surrogate Endpoints And FDA’s Accelerated Approval Process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Measuring changes in Plasmodium falciparum transmission: precision, accuracy and costs of metrics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Factors determining the occurrence of submicroscopic malaria infections and their relevance for control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Dynamics of malaria transmission and susceptibility to clinical malaria episodes following treatment of Plasmodium falciparum asymptomatic carriers: results of a cluster-randomized study of community-wide screening and treatment, and a parallel ento

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Human immune responses that reduce the transmission of Plasmodium falciparum in African populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Genetic surveillance detects both clonal and epidemic transmission of malaria following enhanced intervention in Senegal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Community perceptions of malaria and vaccines in two districts of Mozambique.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Community perceptions of malaria and vaccines in the South Coast and Busia regions of Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Perceptions of malaria and vaccines in Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum mal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Simulation of the cost-effectiveness of malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Developing inexpensive malaria vaccines from plants and algae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Defying malaria: Fathoming severe Plasmodium vivax disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Evidence and implications of mortality associated with acute Plasmodium vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

A long neglected world malaria map: Plasmodium vivax endemicity in 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

The global public health significance of Plasmodium vivax.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

Malaria resurgence: a systematic review and assessment of its causes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.030

10.1016/J.VACCINE.2014.07.030

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference